However, even CD22 expression can be low or even null in several human lung cancer cells, including pancreatic, prostate, breast, and liver cancers to be considered targetable (https://www.proteinatlas.org/ENSG00000012124-CD22/pathology, accessed on 3 November 2021) [46]. The gene discussed is CD22; the disease is liver cancer.